Table 4.

Select adverse events among nab-paclitaxel initiators by line of therapy during the follow-up period^a,b

Adverse event	First line (n = 172)			Second line (n = 211)			Third or later line (n = 281)			All (N = 664)
	Total nc	n	%	Total nc	n	%	Total nc	n	%	Total nc	n	%
Neutropenia	165	33	20.0	190	26	13.7	222	42	18.9	577	101	17.5
Anemia	123	39	31.7	133	31	23.3	147	36	24.5	403	106	26.3
Thrombocytopenia	163	4	2.5	199	11	5.5	264	9	3.4	626	24	3.8
Infections	152	32	21.1	184	25	13.6	242	27	11.2	578	84	14.5
Peripheral neuropathy	129	20	15.5	155	19	12.3	200	31	15.5	484	70	14.5
Asthenia	141	28	19.9	178	25	14.0	232	33	14.2	551	86	15.6
Nausea and vomiting	143	47	32.9	159	30	18.9	179	41	22.9	481	118	24.5
Diarrhea	162	9	5.6	199	7	3.5	267	16	6.0	628	32	5.1
Fluid retention	160	9	5.6	196	12	6.1	257	16	6.2	613	37	6.0
Myalgia/arthralgia	133	14	10.5	159	20	12.6	230	17	7.4	522	51	9.8
Alopecia	171	0	0	209	3	1.4	280	5	1.8	660	8	1.2

^aData are from the Optum Research Database, January 1, 2005 to September 30, 2012

^bFollow-up time was calculated from index date until disenrollment from the health plan, death (or treatment discontinuation), or the end of the study period (September 30, 2012)

^cTotal n refers to the total number of patients without baseline events for its respective subgroup